Heron Therapeutics (NASDAQ:HRTX - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $37.37 million for the quarter. Investors that wish to register for the company's conference call can do so using this link.
Heron Therapeutics Trading Up 0.6 %
Shares of NASDAQ:HRTX traded up $0.01 during trading on Friday, reaching $1.73. 1,151,527 shares of the company traded hands, compared to its average volume of 1,285,698. The firm has a market capitalization of $263.13 million, a price-to-earnings ratio of -9.61 and a beta of 1.60. Heron Therapeutics has a 52-week low of $1.04 and a 52-week high of $3.93. The business's fifty day moving average is $1.65 and its 200-day moving average is $1.73.
Wall Street Analysts Forecast Growth
HRTX has been the subject of several research reports. StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, January 29th. Needham & Company LLC reissued a "buy" rating and issued a $4.00 target price on shares of Heron Therapeutics in a report on Wednesday, December 4th.
View Our Latest Stock Analysis on Heron Therapeutics
About Heron Therapeutics
(
Get Free Report)
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
See Also
Before you consider Heron Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.
While Heron Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
